SMMT Summit Therapeutics (SMMT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001599298
Cluster · 3 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
159
13F, latest reported quarter
What the filings say about SMMT
Insiders, 180 days
+$103.6M net bought
3 buyers
Summit Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Summit Therapeutics Inc. insiders bought a net $103.6M of stock across 37 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jun 4, 2026.
- +14.3% median (+41.3% mean) 90-day return after 8 previous buys.
- The trade is 0.7% of the 573,883,879 shares held after it.
- 2 other insiders bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Zanganeh Mahkam bought about $50.0M of SMMT on Jun 12, 2026, the largest insider purchase at the company since 2023; 2 other insiders bought within 30 days and 159 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 4, 2026.
- -2.5% median (+2.5% mean) 90-day return after 6 previous buys.
- The trade is 0.7% of the 573,883,879 shares held after it.
- 2 other insiders bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer DUGGAN ROBERT W bought about $50.0M of SMMT on Jun 12, 2026, the largest insider purchase at the company since 2023; 2 other insiders bought within 30 days and 159 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Oct 21, 2025.
- -3.3% median (+3.3% mean) 90-day return after 5 previous buys.
- The trade is 0.4% of the 25,824,474 shares held after it.
- 2 other insiders bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer DUGGAN ROBERT W bought about $1.5M of SMMT on Jun 4, 2026; 2 other insiders bought within 30 days and 159 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Oct 21, 2025.
- +30.3% median (+47.4% mean) 90-day return after 7 previous buys.
- The trade is 0.4% of the 25,824,474 shares held after it.
- 2 other insiders bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Zanganeh Mahkam bought about $1.5M of SMMT on Jun 4, 2026; 2 other insiders bought within 30 days and 159 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 13, 2023.
- The trade is 0.8% of the 3,123,603 shares held after it.
- 2 other insiders bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO and CFO Soni Manmeet Singh bought about $360.8K of SMMT on Jun 4, 2026; 2 other insiders bought within 30 days and 159 funds added in the latest 13F quarter.37 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$103.6M over 180 days
+$102.9M of it by a 10%+ holder
more than 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
159 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
26.8% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 51% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders independently bought a net $103.6M while the stock fell 30% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch SMMT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-19.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SMMT: institutional holders (13F)
13F holdings, latest reported quarter
32,786,348 sh
$477.7M
10,043,947 sh
$146.3M
9,536,796 sh
$139.0M
9,529,041 sh
$138.8M
5,734,484 sh
$83.6M
Congress trades in SMMT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SMMT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SMMT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$2.1M position · as of 2026-05-31
1.2%
Invesco Nasdaq Biotechnology ETF
$729.1K position · as of 2026-05-31
1.1%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$108.6M position · as of 2026-06-30
1.0%
PROFUND VP BIOTECHNOLOGY
$480.2K position · as of 2026-06-30
1.0%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$922.8K position · as of 2026-07-31
0.8%
ProShares Ultra Nasdaq Biotechnology
$502.8K position · as of 2026-05-31
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 6 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
1 active
6
Phase 3
4 active
1
Multi-phase
1 active
What changed recently
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
2026-10-09 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Zanganeh
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$20.6M
$30.1M
$12.0M
-44%
+16%
2022
$1.2M
$3.8M
$1.4M
-10%
+12%
2021
$9.6M
$5.1M
$1.3M
-43%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $103.6M bought by insiders over 180 days, 159 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SMMT financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $705.0K |
| FY Dec 2021 | $1.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -4,898% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$459.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SMMT
| FY Dec 2025 | -$323.6M |
| FY Dec 2024 | -$142.2M |
| FY Dec 2023 | -$76.9M |
| FY Dec 2022 | -$42.2M |
| FY Dec 2021 | -$72.9M |
| Jun 2026 | -$142.0M |
| Mar 2026 | -$122.5M |
| Dec 2025 | -$102.1M |
| Sep 2025 | -$93.2M |
| Jun 2025 | -$66.7M |
| Mar 2025 | -$61.6M |
| Dec 2024 | -$48.7M |
| Sep 2024 | -$30.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-192.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SMMT
| FY Dec 2025 | -206.1% |
| FY Dec 2024 | -94.9% |
| FY Dec 2023 | -601.8% |
| FY Dec 2022 | -75.1% |
| FY Dec 2021 | -108.9% |
| Jun 2026 | -192.5% |
| Mar 2026 | -271.0% |
| Dec 2025 | -206.1% |
| Sep 2025 | -292.5% |
| Jun 2025 | -328.3% |
| Mar 2025 | -123.9% |
| Dec 2024 | -94.9% |
| Sep 2024 | -73.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-159.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SMMT
| FY Dec 2025 | -181.9% |
| FY Dec 2024 | -69.3% |
| FY Dec 2023 | -141.8% |
| FY Dec 2022 | -20.3% |
| FY Dec 2021 | -82.1% |
| Jun 2026 | -159.1% |
| Mar 2026 | -233.8% |
| Dec 2025 | -181.9% |
| Sep 2025 | -241.1% |
| Jun 2025 | -224.1% |
| Mar 2025 | -85.9% |
| Dec 2024 | -69.3% |
| Sep 2024 | -54.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-49.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SMMT
| FY Dec 2025 | -42.2% |
| FY Dec 2024 | -78.4% |
| FY Dec 2023 | -150.9% |
| FY Dec 2022 | -20.2% |
| FY Dec 2021 | -101.2% |
| Jun 2026 | -49.5% |
| Mar 2026 | -49.5% |
| Dec 2025 | -42.2% |
| Sep 2025 | -70.6% |
| Jun 2025 | -97.1% |
| Mar 2025 | -90.0% |
| Dec 2024 | -78.4% |
| Sep 2024 | -71.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield SMMT
| FY Dec 2025 | -2.5% |
| FY Dec 2024 | -1.1% |
| FY Dec 2023 | -4.2% |
| FY Dec 2022 | -4.9% |
| FY Dec 2021 | -27.7% |
| Jun 2026 | -4.1% |
| Mar 2026 | -2.6% |
| Dec 2025 | -2.5% |
| Sep 2025 | -1.8% |
| Jun 2025 | -1.3% |
| Mar 2025 | -1.2% |
| Dec 2024 | -1.1% |
| Sep 2024 | -0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SMMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $0 | $0 | $705.0K |
| Operating income | n/a | -$226.0M | -$609.6M | -$72.1M |
| Net income | -$1.1B | -$221.3M | -$614.9M | -$78.8M |
| EPS (diluted) | -1.44 | -0.31 | -0.99 | -0.41 |
| Operating cash flow | -$322.9M | -$142.1M | -$76.8M | -$41.6M |
| Cash | $225.3M | $104.9M | $71.4M | $348.6M |
SEC XBRL, fiscal years, as known on 2026-10-27
SMMT Stock Sonar score 4/7 axes
Find similar shapesCompareSMMT ranks highest on insider conviction (94th percentile) and institutional and government (84th), and lowest on risk and compliance (23rd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SMMT filings, in plain words
Are Summit Therapeutics insiders buying or selling SMMT?
In the 180 days to 2026-10-27, Summit Therapeutics insiders were net buyers, a net $103.6M across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-27, Summit Therapeutics insiders were net buyers of SMMT, a net $103.6M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $102.9M, came from a holder of 10% or more rather than an officer or director. 3 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
